GlobeNewsWire
03 Nov 2025, 13:30 UTC · 49w ago
Verdict
Headline leans bullish. We score FEMY +1.00.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
Which stocks this story touches
More positive than 99% of ticker scores this week
The company received FDA approval to proceed to the final phase of a pivotal trial and secured significant funding via convertible notes.
Continue reading
5 related stories
More positive than 99% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
11h ago
−88.2%
Price is moving against the score
$1.50 vs $12.74 close before publication (Oct 31) · not market-adjusted
FEMY chart →
